source
- Caldera and Evommune secure China licensing agreements for autoimmune drug assetsCaldera and Evommune announced they have entered licensing agreements with Chinese partners to bring their autoimmune drug programs to the Chinese market. The deals come as the biopharma sector is…
- Merck reports positive mid-stage results for Hanmi-licensed MASH drugMerck announced Thursday that its dual GLP-1/glucagon agonist, which it licensed from South Korea’s Hanmi Pharmaceutical in 2020, has met its primary endpoints in a mid-stage trial for metabolic dy…